Across TCGA pan-cancer cohorts, MAP10 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAP10 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAP10 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP10 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where MAP10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.951	0.657	.006	6	view →
PDAC	OS	Tertile	II,III,IV	0.757	0.294	.013	6	view →
LUAD	DFS	Median	All	0.777	0.522	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MAP10 tumor-vs-normal RNA expression · all MAP10 data types